Metropolis Healthcare reported robust financial growth for Q4 FY26 (January-March 2026), with consolidated revenue increasing by 23% year-on-year to INR 425 crore. The company saw a significant surge in profitability, as EBITDA rose 71% and Profit After Tax (PAT) grew 75% compared to the same period last year. These results were driven by strong patient volume growth, increased specialized testing contributions, and successful network expansion across India.
Quarterly Financial Performance
Metropolis Healthcare has delivered a strong performance for the final quarter of the fiscal year ending March 31, 2026. The consolidated results indicate significant operational improvements, with Revenue from Operations reaching INR 425 crore, marking a 23% year-on-year (YoY) increase. Profitability metrics also showed substantial gains, with Reported EBITDA climbing to INR 108 crore—a 71% YoY increase—and Profit After Tax rising to INR 51 crore, reflecting a strong 75% YoY growth.
Operational and Segment Highlights
The company’s growth was supported by solid operational metrics, including an 11% YoY increase in patient volumes and a 14% YoY rise in test volumes. Key business segments showed healthy traction: B2C revenues grew by 20%, while B2B revenues increased by 28%, aided by hospital outsourcing and high client retention. Additionally, the specialized portfolios, specifically TruHealth and Specialty diagnostics, saw growth of 24% and 31% respectively, signaling a shift toward preventive and advanced healthcare.
Expansion and Future Outlook
Metropolis Healthcare has reached a major milestone by expanding its network to over 5,000 centers across India. According to company management, the focus remains on leveraging scientific excellence and digital engagement to maintain this momentum. Following these strong results, the Board has approved a dividend of INR 1 per share. Looking ahead, the company aims to drive further sustainable growth and efficiency-led margin expansion through continued network optimization and a focus on high-end diagnostics.
Source: BSE
